Cubist gains broader fast-track status for antibiotic

05/8/2013 | Boston Herald

The FDA has widened the fast-track status for Cubist Pharmaceuticals' CXA-201 drug to include hospital-acquired bacterial pneumonia and complicated urinary tract infections. The therapy targets pathogens including multidrug resistant Pseudomonas aeruginosa.

View Full Article in:

Boston Herald

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI